A Phase 2 Randomized Study of Dalantercept in Combination with Axitinib Compared to Axitinib Alone as Second Line Treatment in Patients with Metastatic Renal Cell Carcinoma - Regional Cancer Care Associates LLC

Clinical Trials

A Phase 2 Randomized Study of Dalantercept in Combination with Axitinib Compared to Axitinib Alone as Second Line Treatment in Patients with Metastatic Renal Cell Carcinoma

Type of Cancer
Genito-Urinary
Locations
Hackensack
Sponsor
Acceleron
Protocol Number
Acceleron A041-04
Cancer Diagnosis
To Learn More Call
201-510-0910